Abstract:Yun Lan, 1, &ast Xuemei Ling, 1, 2, &ast Xizi Deng, 1, &ast Yaqing Lin, 1 Junbin Li, 1, 2 Liya Li, 1 Ruiying He, 1 Weiping Cai, 1 Feng Li, 1, &ast Linghua Li, 1 Fengyu Hu 1 1 Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, 510440, People's Republic of China; 2 Guangdong Center for Diagnosis and Treatment of AIDS, Guangzhou, 510060, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fengyu Hu; Linghua Li, Guangzhou Eighth People's Hospital, Guangzhou Medical University, No. 8 Huaying Road, Baiyun District, Guangzhou, 510440, People's Republic of China, Email ; Background: Antiretroviral therapy (ART) efficiently reduces the morbidities and mortalities caused by HIV-1 infection and prevents the HIV epidemic. However, virologic failure (VF) occurs in some patients receiving ART experience, especially increases in those patients with intermittent or persistent low-level viremia (LLV). The presence of drug resistance mutations (DRMs) in LLV was a strong predictor of subsequent VF. The data on drug resistance (DR) or DRMs for HIV-1 infections at low-level viral load (LLVL) are limited in China. Objective: To monitor the prevalence of HIV-1 drug resistance and to evaluate the risk factors associated with drug resistance in LLVL HIV-1 infections during ART in Guangdong, China. Methods: Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing. Then, the genotypic resistance test was performed and DR was analyzed by the Stanford HIVDB program. Finally, DR-associated factors were identified by logistic regression analysis. Results: We found that CRF01_AE (53.57%) and CRF07_BC (25.07%) were the dominant HIV-1 genotypes in LLVL in Guangdong between 2011 and 2022 but that the percentage of CRF01_AE showed a trend of decrease over time. M46 (1.49%), M184 (30.91%), and K103 (21.46%) were the dominant PI-, NRTI-, and NNRTI-associated mutations, respectively. The total DR rate was 47.06%. Specifically, PI (3.71%) showed a significantly lower DR rate than NNRTI (40.74%) and NRTI (34.14%). Duration of ART, initial ART regimen, ethnicity, and WHO clinical stages were associated with DR. Conclusion: The drug resistance rate among the LLVL during ART in Guangdong, China is high. The risk factors associated with HIV drug resistance should be seriously considered for better control. Keywords: HIV, low-level viral load, drug resistance mutation, drug resistance HIV infection remains one challenge for public health worldwide. 1 Since its first report in 1985 in China, HIV infection keeps increasing. By October 2021, 1.14 million HIV/AIDS patients are reported in China. 2 The national-wide antiretroviral therapy (ART) effectively alleviates HIV/AIDS-related morbidity, substantially prolongs the life span of HIV/AIDS patients, and considerably reduces HIV/AIDS-related deaths. 3 ART can suppress the viral load (VL) below the detection limit of clinical assays in most treated HIV-infected individuals. 3,4 However, some patients undergoing ART experience virologic failure (VF), and intermittent or persistent low-level viremia (LLV). 3,5–7 VF varies according to different international guidelines, 1000 copies/mL (World Health Organization, WHO), 8 200 copies/mL [Department of Health and Human Services, (DHHS, USA)], 9 and 50 copies/mL (European AIDS Clinical Society, EACS). 10 According to the WHO guideline adopted by China, VF is defined as the HIV viral load over 1000 copies/mL after six months of ART and the VL between 50 and 999 copies/mL is defined as LLV. 8 In addition, the continuously emerging drug-resistant and multidrug-resistant strains contributed to the viral failure and its subsequent increased risk of HIV-related morbidity and mortality. 11–14 And the presence of drug resistance mutations (DRMs) in LLV was a strong predictor of subsequent VF. 15,16 By the end of October 2022, 84,481 HIV-infected individuals were confirmed in Guangdong, and 74,000 (90%) were receiving ART. 17 The prevalence of HIV LLV in China was detected to be 5.3–38.7% in different regions. 18 The percentage of LLV among HIV/AIDS patients receiving ART for more than one year was 3.3% in Guangdong. 13 Drug resistance (DR) among LLV should -Abstract Truncated-

HIV‐1 low‐level viraemia predicts virological failure in first‐line and second‐line ART‐experienced individuals in India: A retrospective longitudinal study

The Impact of Low-Level Viraemia on Virological Failure—Results From a Multicenter HIV Antiretroviral Therapy Cohort Study in Yunnan, China

Low-level viral loads and virological failure in the integrase strand transfer era

Risk Factors and Clinical Prediction Models for Low-Level Viremia in People Living with HIV Receiving Antiretroviral Therapy: an 11-Year Retrospective Study

Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana

Influencing factors and clinical significance of hypoviremia in HIV

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens

Clinical Relevance of Human Immunodeficiency Virus Low-level Viremia in the Dolutegravir era: Data From the Viral Load Cohort North-East Lesotho (VICONEL)

Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens

Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

Low level viremia is associated with Serious Non-AIDS Events in People Living with HIV

Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy

Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China

Consequences of low-level viremia among women with HIV in the United States

Determinants of Virological Failure after 1 Year's Antiretroviral Therapy in Vietnamese People with HIV: Findings from a Retrospective Cohort of 13 Outpatient Clinics in Six Provinces.

Successful Virologic Outcomes over Time among HAART-treated HIV-infected Patients.

Managing low-level HIV viraemia in antiretroviral therapy: a systematic review and meta-analysis

Very High Baseline HIV viremia impairs efficacy of NNRTI-based ART: A long-term observation in treatment-naïve patients

Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI era

Clinical Significance and Management of Low-Level HIV Viremia in the Era of Integrase Strand Transfer Inhibitors

Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study